1
|
Thermodynamic models for determination of solid-liquid equilibrium of para-tert-butylbenzoic acid in binary and ternary solvent system. J Mol Liq 2022. [DOI: 10.1016/j.molliq.2022.120888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
|
2
|
Novales NA, Schwans JP. Comparing the effects of organic cosolvents on acetylcholinesterase and butyrylcholinesterase activity. Anal Biochem 2022; 654:114796. [DOI: 10.1016/j.ab.2022.114796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 06/15/2022] [Accepted: 06/16/2022] [Indexed: 11/17/2022]
|
3
|
Jiménez Cruz JM, Vlaar CP, López-Mejías V, Stelzer T. Solubility Measurements and Correlation of MBQ-167 in Neat and Binary Solvent Mixtures. JOURNAL OF CHEMICAL AND ENGINEERING DATA 2021; 66:832-839. [PMID: 36262318 PMCID: PMC9578765 DOI: 10.1021/acs.jced.0c00908] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
MBQ-167 is a novel, small-molecule dual inhibitor of Rac and Cdc42, small GTPases that are involved in cytoskeletal organization, cell cycle progression, and cell migration. In an in vivo mouse model, MBQ-167 has been shown to significantly reduce mammary tumor growth and metastasis and is currently undergoing preclinical studies for the treatment of metastatic cancer. To date, no solubility data have been reported for this compound. For this reason, the present study aims to determine the solubility of this compound in eight neat solvents (acetonitrile, 1-butanol, 2-butanol, ethanol, ethyl acetate, methanol, 1-propanol, and 2-propanol) and two binary solvent mixtures [ethyl acetate (2) + heptane (3) and ethanol (2) + water (3)] between the temperatures of 278.15 and 333.15 K. The results obtained employing the polythermal method show that the solubility of MBQ-167 increases with an increase in temperature in all neat solvents used within this study. Moreover, in the two binary solvent mixtures, the solubility of this compound increases with increasing temperature and decreases with an increasing mass fraction of the antisolvent (heptane or water). The experimental solubility data were correlated using the modified Apelblat and λh model equations. The predicted solubility data acquired from the Apelblat and λh model equations correlate well with the experimental solubility data as indicated by the low ARD % (≤1.8304 and ≤6.5366, respectively). No solvent-mediated polymorphic phase transitions were observed while performing the solubility studies, and no other solid forms were detected after the recrystallization in the solvents and solvent mixtures. The solubility data determined here can offer pathways to develop pharmaceutical crystallization processes that can further the translation of MBQ-167 into a clinical setting.
Collapse
Affiliation(s)
- Jocelyn M Jiménez Cruz
- Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States; Department of Pharmaceutical Sciences, University of Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico 00936, United States
| | - Cornelis P Vlaar
- Department of Pharmaceutical Sciences, University of Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico 00936, United States
| | - Vilmalí López-Mejías
- Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States; Department of Chemistry, University of Puerto Rico - Río Piedras Campus, San Juan, Puerto Rico 00931, United States
| | - Torsten Stelzer
- Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States; Department of Pharmaceutical Sciences, University of Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico 00936, United States
| |
Collapse
|
4
|
Vázquez Marrero VR, Berríos CP, Dios Rodríguez LD, Stelzer T, López-Mejías V. In the Context of Polymorphism: Accurate Measurement, and Validation of Solubility Data. CRYSTAL GROWTH & DESIGN 2019; 19:4101-4108. [PMID: 32863778 PMCID: PMC7453630 DOI: 10.1021/acs.cgd.9b00529] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Solubility measurements for polymorphic compounds are often accompanied by solvent-mediated phase transformations. In this study, solubility measurements from undersaturated solutions are employed to investigate the solubility of the two most stable polymorphs of flufenamic acid (FFA forms I and III), tolfenamic acid (TA forms I and II), and the only known form of niflumic acid (NA). The solubility was measured from 278.15 to 333.15 K in four alcohols of a homologous series (methanol, ethanol, 1-propanol, n-butanol) using the polythermal method. It was established that the solubility of these compounds increases with increasing temperature. The solubility curves of FFA forms I and III intersect at ~315.15 K (42 °C) in all four solvents, which represents the transition temperature of the enantiotropic pair. In the case of TA, the solubility of form II could not be reliably obtained in any of the solvents because of the fast solvent-mediated phase transformation. The solubility of the only known form of NA was also determined, and no other polymorphs of NA were observed. The experimental solubility data of FFA (forms I and III), TA (form I), and NA in these four solvents was correlated using the modified Apelblat and λh model equations. The correlated and experimentally determined solubility data obtained serves to (i) guide the accurate determination of the solubility for polymorphic compounds, (ii) assess the role of the solvent in mediating transformations, and (iii) provide a route to engineer advanced crystallization processes for these pharmaceutical compounds.
Collapse
Affiliation(s)
- Víctor R. Vázquez Marrero
- Department of Biology, University of Puerto Rico—Río Piedras Campus, San Juan, Puerto Rico 00931, United States
- Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States
| | - Carmen Piñero Berríos
- Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States
- Department of Chemistry, University of Puerto Rico—Río Piedras Campus, San Juan, Puerto Rico 00931, United States
| | - Luz De Dios Rodríguez
- Department of Biology, University of Puerto Rico—Río Piedras Campus, San Juan, Puerto Rico 00931, United States
- Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States
| | - Torsten Stelzer
- Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States
- Department of Pharmaceutical Sciences, University of Puerto Rico—Medical Sciences Campus, San Juan, Puerto Rico 00936, United States
| | - Vilmalí López-Mejías
- Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States
- Department of Chemistry, University of Puerto Rico—Río Piedras Campus, San Juan, Puerto Rico 00931, United States
| |
Collapse
|